These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 31200859)

  • 41. Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation.
    Maniaci C; Hughes SJ; Testa A; Chen W; Lamont DJ; Rocha S; Alessi DR; Romeo R; Ciulli A
    Nat Commun; 2017 Oct; 8(1):830. PubMed ID: 29018234
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs.
    Ito T; Handa H
    Int J Hematol; 2016 Sep; 104(3):293-9. PubMed ID: 27460676
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Synthesis of novel glutarimide ligands for the E3 ligase substrate receptor Cereblon (CRBN): Investigation of their binding mode and antiproliferative effects against myeloma cell lines.
    Krasavin M; Adamchik M; Bubyrev A; Heim C; Maiwald S; Zhukovsky D; Zhmurov P; Bunev A; Hartmann MD
    Eur J Med Chem; 2023 Jan; 246():114990. PubMed ID: 36476642
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A novel effect of thalidomide and its analogs: suppression of cereblon ubiquitination enhances ubiquitin ligase function.
    Liu Y; Huang X; He X; Zhou Y; Jiang X; Chen-Kiang S; Jaffrey SR; Xu G
    FASEB J; 2015 Dec; 29(12):4829-39. PubMed ID: 26231201
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Development of targeted protein degradation therapeutics.
    Chamberlain PP; Hamann LG
    Nat Chem Biol; 2019 Oct; 15(10):937-944. PubMed ID: 31527835
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Thalidomide Inhibits Human iPSC Mesendoderm Differentiation by Modulating CRBN-dependent Degradation of SALL4.
    Belair DG; Lu G; Waller LE; Gustin JA; Collins ND; Kolaja KL
    Sci Rep; 2020 Feb; 10(1):2864. PubMed ID: 32071327
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cereblon Promotes the Ubiquitination and Proteasomal Degradation of Interleukin Enhancer-Binding Factor 2.
    Lian Q; Gao Y; Li Q; He X; Jiang X; Pu Z; Xu G
    Protein J; 2020 Oct; 39(5):411-421. PubMed ID: 33009960
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Targeted protein degradation and the enzymology of degraders.
    Fisher SL; Phillips AJ
    Curr Opin Chem Biol; 2018 Jun; 44():47-55. PubMed ID: 29885948
    [TBL] [Abstract][Full Text] [Related]  

  • 49. SuFEx-based chemical diversification for the systematic discovery of CRBN molecular glues.
    Carter TR; Milosevich N; Dada L; Shaum JB; Barry Sharpless K; Kitamura S; Erb MA
    Bioorg Med Chem; 2024 Apr; 104():117699. PubMed ID: 38608634
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cereblon target validation using a covalent inhibitor of neosubstrate recruitment.
    Dann GP; Liu H; Nowak RP; Jones LH
    Methods Enzymol; 2023; 681():155-167. PubMed ID: 36764755
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Trends in Neosubstrate Degradation by Cereblon-Based Molecular Glues and the Development of Novel Multiparameter Optimization Scores.
    Szewczyk SM; Verma I; Edwards JT; Weiss DR; Chekler ELP
    J Med Chem; 2024 Jan; 67(2):1327-1335. PubMed ID: 38170610
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Leveraging Ligand Affinity and Properties: Discovery of Novel Benzamide-Type Cereblon Binders for the Design of PROTACs.
    Steinebach C; Bricelj A; Murgai A; Sosič I; Bischof L; Ng YLD; Heim C; Maiwald S; Proj M; Voget R; Feller F; Košmrlj J; Sapozhnikova V; Schmidt A; Zuleeg MR; Lemnitzer P; Mertins P; Hansen FK; Gütschow M; Krönke J; Hartmann MD
    J Med Chem; 2023 Nov; 66(21):14513-14543. PubMed ID: 37902300
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Discovery of Highly Potent CRBN Ligands and Insight into Their Binding Mode through Molecular Docking and Molecular Dynamics Simulations.
    Yan J; Zheng Z
    ChemMedChem; 2023 Mar; 18(5):e202200573. PubMed ID: 36750890
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cereblon-mediated degradation of the amyloid precursor protein via the ubiquitin-proteasome pathway.
    Kurihara T; Asahi T; Sawamura N
    Biochem Biophys Res Commun; 2020 Mar; 524(1):236-241. PubMed ID: 31983437
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Target protein localization and its impact on PROTAC-mediated degradation.
    Simpson LM; Glennie L; Brewer A; Zhao JF; Crooks J; Shpiro N; Sapkota GP
    Cell Chem Biol; 2022 Oct; 29(10):1482-1504.e7. PubMed ID: 36075213
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Humanized cereblon mice revealed two distinct therapeutic pathways of immunomodulatory drugs.
    Gemechu Y; Millrine D; Hashimoto S; Prakash J; Sanchenkova K; Metwally H; Gyanu P; Kang S; Kishimoto T
    Proc Natl Acad Sci U S A; 2018 Nov; 115(46):11802-11807. PubMed ID: 30373817
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase.
    Matyskiela ME; Lu G; Ito T; Pagarigan B; Lu CC; Miller K; Fang W; Wang NY; Nguyen D; Houston J; Carmel G; Tran T; Riley M; Nosaka L; Lander GC; Gaidarova S; Xu S; Ruchelman AL; Handa H; Carmichael J; Daniel TO; Cathers BE; Lopez-Girona A; Chamberlain PP
    Nature; 2016 Jul; 535(7611):252-7. PubMed ID: 27338790
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Redirecting the Neo-Substrate Specificity of Cereblon-Targeting PROTACs to Helios.
    Verano AL; You I; Donovan KA; Mageed N; Yue H; Nowak RP; Fischer ES; Wang ES; Gray NS
    ACS Chem Biol; 2022 Sep; 17(9):2404-2410. PubMed ID: 36007246
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Profiling CELMoD-Mediated Degradation of Cereblon Neosubstrates.
    Thompson JW; Clayton T; Khambatta G; Bateman LA; Carroll CW; Chamberlain PP; Matyskiela ME
    Methods Mol Biol; 2021; 2365():283-300. PubMed ID: 34432250
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Positive selection of cereblon modified function including its E3 ubiquitin ligase activity and binding efficiency with AMPK.
    Onodera W; Asahi T; Sawamura N
    Mol Phylogenet Evol; 2019 Jun; 135():78-85. PubMed ID: 30836149
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.